ADVAC

The power and limitations of immunobridging studies: the example of COVID-19 vaccines

ALUMNI Meeting : Webinar
Date: 13 September 2022
Time:  15h00 to 17h00 CET
Place: WEBINAR
 
Discussion topic:
The power and limitations of immunobridging studies: the example of COVID-19 vaccines
Chair: Hanna Nohynek,
Finnish Institute for Health and Welfare, Finland and Member of the ADVAC Scientific Committee
Presentations :

Bridging studies – why and how?
Peter Dull, Bill & Melinda Gates Foundation

Criteria and requirement for the licensing of new vaccines with special emphasis on COVID-19
the view of EMA. Marco Cavaleri, Head of Office Biological Health Threats and Vaccine Strategy, European Medicines Agency.
Panel discussion: Strategies behind the variant adapted COVID-19 vaccines development
with participation from regulators, Godwin Enwere, WHO Prequalification Unit, Vikram Paradkar, Executive Vice-President Production, Biological E, representing DCVMN, Jeff Roberts, Associate Vice-President Clinical Research, MSD, representing IFPMA, and other experts.
Documents and links:

pdfVaccine development and immunobridging
what is it, why we do it….  And why it makes us nervous
by Peter Dull

pdfCriteria and requirement for the licensing of new vaccines with special emphasis on COVID-19
the view of EMA
by Marco Cavaleri